Formulation And Characterization of a Mucoadhesive Buccal Patch of Glipizide for Sustained Antidiabetic Action

Worldwide, diabetes mellitus is becoming an increasingly serious health concern. Chronically elevated blood sugar levels due to insulin resistance, insulin ineffectiveness, or, more often than not, both, are the root cause of this condition. Significant macrovascular and microvascular consequences, including as cardiovascular disease, neuropathy, nephropathy, and retinopathy, can develop from this metabolic illness if it is not well controlled. These problems greatly diminish quality of life and raise death rates. To effectively treat diabetes, one must take a comprehensive approach that includes medication, physical activity, and dietary changes in order to keep blood glucose levels within a physiological range. The majority of people with Type 2 Diabetes Mellitus (T2DM) rely on oral hypoglycemic agents (OHAs) as their primary medication. Using the solvent casting process, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, carbopol-934P, and Eudragit RL-100 were utilised to create glipizide mucoadhesive buccal films. The films that were prepared were tested for in vitro residence duration, folding endurance, thickness, surface pH, swelling index, in vitro release, and permeation investigations, among other parameters. with consistent drug content. Over the course of more than six hours, the films demonstrated controlled release. Results showed that films containing 5 mg glipizide in a 4.9% w/v hydroxypropylmethylcellulose and 1.5% w/v sodium carboxymethylcellulose solution swelled adequately, had an ideal residence duration, and showed promise for drug release. Researchers determined that the formulation might be used to create buccal films with therapeutic potential.